{"gene":"CCL11","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":1996,"finding":"CCL11 (eotaxin) binds with high affinity to the G protein-coupled receptor CKR-3 (CCR3), which is selectively expressed on eosinophils. Cells transfected with CKR-3 cDNA specifically bound radiolabeled CCL11 and migrated in chemotaxis assays toward CCL11, RANTES, and MCP-3, but not other chemokines, establishing CCR3 as the primary CCL11 receptor on eosinophils.","method":"Radioligand binding assays, cDNA transfection, transwell chemotaxis assays, Northern blot, monoclonal antibody staining","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted binding and chemotaxis in transfected cells, replicated independently in two simultaneous papers (PMID 8676064 and 8642344)","pmids":["8676064","8642344"],"is_preprint":false},{"year":1996,"finding":"CCR3 expressed on eosinophils binds CCL11 with Kd ~0.1 nM, RANTES with Kd ~3.1 nM, and MCP-3 with Kd ~2.7 nM, and triggers intracellular Ca2+ flux in response to CCL11, RANTES, and MCP-3, but not MIP-1α or MIP-1β, indicating ligand selectivity and G protein-coupled signaling.","method":"Stable transfection in AML14.3D10 cells, competition binding, Ca2+ flux assay","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis-level receptor pharmacology, replicated across two independent labs","pmids":["8642344"],"is_preprint":false},{"year":1997,"finding":"CCR3 is expressed by human TH2 (but not TH1) cells; CCL11 stimulates intracellular calcium increases and chemotaxis specifically in CCR3+ T cells, providing a mechanism for selective TH2 cell recruitment in allergic reactions.","method":"Anti-CCR3 antibody isolation of T cell subsets, intracellular Ca2+ measurement, chemotaxis assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal antibody blocking plus functional Ca2+ and chemotaxis assays; high-citation replication across allergy field","pmids":["9302298"],"is_preprint":false},{"year":1997,"finding":"TNF-α and IL-1β induce CCL11 mRNA accumulation in pulmonary epithelial cell lines (A549, BEAS-2B) in a dose-dependent manner; IFN-γ enhances this induction; dexamethasone suppresses cytokine-induced CCL11 mRNA and protein secretion; cycloheximide augments induction, suggesting a labile repressor protein. These cytokine-induced increases correlate with increased CCL11 protein secretion.","method":"RT-PCR, ELISA, cycloheximide/dexamethasone pharmacologic manipulation of cultured cell lines","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods in single lab, clean dose-response; no independent replication cited","pmids":["9120022"],"is_preprint":false},{"year":1999,"finding":"CCL11 gene transcription is activated by NF-κB (in response to TNF-α) and STAT6 (in response to IL-4) through distinct binding sites in the eotaxin promoter. Mutation of the NF-κB site abolished TNF-α-driven activation; mutation of the STAT6 site abolished IL-4-driven activation; double mutation abolished all transcriptional activation. EMSA confirmed factor binding to the respective promoter elements.","method":"Luciferase reporter assays with promoter deletion/mutation constructs, EMSA, transfection in BEAS-2B cells","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — promoter mutagenesis combined with EMSA and functional reporter assays in the same study; two distinct signaling nodes dissected","pmids":["10586089"],"is_preprint":false},{"year":1999,"finding":"CCL11-induced eosinophil migration requires activation of the p42/p44 MAPK (ERK1/2) pathway. The MEK inhibitor PD98059 dramatically reduced eotaxin-induced eosinophil rolling in vivo and chemotaxis in vitro, and inhibited actin polymerization/rearrangement, placing MAPK activation downstream of CCR3 signaling and upstream of cytoskeletal remodeling during chemotaxis.","method":"In vitro phosphorylation assay, MEK inhibitor (PD98059), intravital microscopy, transwell chemotaxis, actin polymerization assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — pharmacologic inhibition with multiple orthogonal readouts (phosphorylation, rolling, chemotaxis, actin); single lab but rigorous mechanistic dissection","pmids":["10415066"],"is_preprint":false},{"year":2001,"finding":"CCL11 is a CCR5 agonist and a CCR2 antagonist. CCL11 at 100 nM triggered CCR5 (Ca2+ flux, receptor internalization) but did not activate CCR2 even at 1 µM, while competitively displacing MCP-1 from CCR2 and inhibiting MCP-1-induced chemotaxis and enzyme release. CCL11 induced CCR5 internalization in human monocytes and transfected cells.","method":"Calcium flux assay, receptor internalization assay, 125I-MCP-1 competition binding, chemotaxis assay in human monocytes and transfected cells","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with multiple orthogonal assays (binding, Ca2+ flux, internalization, chemotaxis); single lab","pmids":["11264152"],"is_preprint":false},{"year":2001,"finding":"CCL11 is a partial agonist of CCR2b. At 1 µM, CCL11 recruited CCR2b-transfected cells in chemotaxis, while sub-stimulatory concentrations inhibited MCP-1-induced chemotaxis and Ca2+ flux via CCR2b. Radiolabeled CCL11 bound CCR2b with Kd ~7.5 nM (vs. ~1.68 nM at CCR3). CCR2-specific (not CCR3-specific) antagonism blocked this CCL11-mediated migration.","method":"Radioligand binding, Ca2+ flux assay, chemotaxis assay with CCR2b/CCR3 transfectants and THP-1 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted in transfected cells with binding, Ca2+ and chemotaxis assays; complementary to PMID 11264152","pmids":["11559700"],"is_preprint":false},{"year":2001,"finding":"CCL11 induces chemotaxis and in vivo angiogenesis via CCR3 expressed on human microvascular endothelial cells. The chemotactic response was inhibited by antibodies to either CCL11 or CCR3. CCL11 induced blood vessel formation in chick chorioallantoic membrane and Matrigel plug assays; rat aortic ring sprouting assay showed angiogenesis is direct and not mediated by eosinophil products.","method":"Chemotaxis assay, antibody neutralization, CAM assay, Matrigel plug assay, rat aortic ring sprouting assay, flow cytometry for CCR3","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple in vivo and in vitro angiogenesis models with antibody blocking; single lab","pmids":["11390513"],"is_preprint":false},{"year":2001,"finding":"TNF-α-induced CCL11 expression in fibroblasts is mediated through STAT6, not solely NF-κB. TNF-α activated the CCL11 promoter via an NF-κB/STAT6 composite element, and this required STAT6 DNA binding; promoter constructs with mutated STAT6 sites were unresponsive to TNF-α. A trans-dominant negative STAT6 protein inhibited TNF-α-induced CCL11 secretion in primary fibroblasts.","method":"Luciferase promoter reporter in STAT6-deficient HEK293 cells with STAT6 cotransfection, dominant-negative STAT6 overexpression, ELISA","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — promoter mutagenesis, dominant-negative rescue, and protein secretion readout in a single study","pmids":["11254707"],"is_preprint":false},{"year":2004,"finding":"CCL11 induces CCR3-dependent smooth muscle cell (SMC) migration. CCR3 mRNA and protein are expressed in mouse aortic SMCs; CCL11 induced concentration-dependent SMC chemotaxis in Boyden chamber and scrape-wound assays that were blocked by anti-CCR3 (but not anti-CCR2) antibody. CCL11 had no effect on SMC proliferation.","method":"RT-PCR, Western blot, flow cytometry, Boyden chamber chemotaxis, scrape-wound assay, antibody neutralization","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple assays with receptor-specific antibody blocking; single lab","pmids":["15130922"],"is_preprint":false},{"year":2005,"finding":"CCL11 signaling via CCR3 mediates eosinophil recruitment specifically to airway nerves (not just to lung tissue broadly) in antigen-challenged guinea pigs. A CCR3 antagonist prevented clustering of eosinophils around nerves and preserved M2 muscarinic receptor function, blocking vagal hyperreactivity. CCL11 protein was detected in airway parasympathetic neurons; IL-4 and IL-13 increased CCL11 expression in cultured airway neurons and human neuroblastoma cells.","method":"In vivo CCR3 antagonist treatment, immunostaining of airway nerves, M2R functional assay (vagal stimulation), cultured guinea pig and human airway neurons","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo pharmacologic blockade with mechanistic endpoint (nerve clustering, M2R function), supported by neuronal expression data; single lab","pmids":["16374515"],"is_preprint":false},{"year":2005,"finding":"CCL11 and CCR3 are required for pulmonary granulocyte recruitment and development of bleomycin-induced lung fibrosis. CCL11-deficient mice developed significantly reduced fibrosis and lower TGF-β1 expression; overexpression of CCL11 enhanced fibrosis. Neutralizing CCR3 antibodies reduced fibrosis, eosinophilia, neutrophilia, and profibrotic cytokines.","method":"CCL11 knockout mice, CCL11 overexpression, anti-CCR3 antibody neutralization, histology, cytokine measurement","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function and antibody blocking with defined fibrotic phenotype; single lab","pmids":["16314464"],"is_preprint":false},{"year":2005,"finding":"CCL11 directly activates mouse eosinophil secretion of enzymatically active RNases (EARs) by piecemeal degranulation (EC50 ~5 nM), via CCR3 on both intact eosinophils and cell-free eosinophil granules. Cell-free granules expressing functional CCR3 secreted EAR and eosinophil peroxidase in response to CCL11.","method":"In vitro RNase activity assay, ultrastructural electron microscopy (piecemeal degranulation), CCR3-expressing cell-free granule stimulation","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional in vitro assay with ultrastructural validation; single lab","pmids":["22294786"],"is_preprint":false},{"year":2006,"finding":"Mast cell β-tryptase selectively cleaves CCL11 (eotaxin) and RANTES, abrogating their eosinophil chemotactic activities. The proteolytic activity of tryptase (requiring heparin) was necessary; heat inactivation and leupeptin reversed the effect. Mast cell chymase also reduced CCL11 immunoreactivity but did not affect RANTES. Neither enzyme affected other tested chemokines/cytokines.","method":"Purified β-tryptase incubation with recombinant and cell-derived CCL11/RANTES, ELISA immunoreactivity, chemotaxis assay with tryptase-pretreated chemokines, protease inhibitor and heat-inactivation controls","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical cleavage assay with functional chemotaxis readout and enzyme inhibitor controls; single lab with multiple orthogonal methods","pmids":["16517749"],"is_preprint":false},{"year":2004,"finding":"IL-9 induces CCL11 expression in human airway smooth muscle (ASM) cells via transcriptional activation of the CCL11 promoter. IL-9Rα is expressed on ASM cells; neutralizing anti-IL-9 (but not anti-IL-4 or anti-IL-13) antibodies significantly reduced IL-9-induced CCL11 production. Actinomycin D blocked IL-9-induced CCL11 mRNA and protein, confirming transcriptional regulation. Conditioned medium from IL-9-stimulated ASM cells attracted eosinophils.","method":"ELISA, real-time RT-PCR, luciferase promoter reporter transfection, neutralizing antibody blockade, actinomycin D chase, chemotaxis assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — transcriptional mechanism confirmed by promoter reporter and actinomycin D, with functional chemotaxis readout; single lab, multiple orthogonal methods","pmids":["15294996"],"is_preprint":false},{"year":2009,"finding":"IL-17A induces CCL11 expression in human airway smooth muscle cells via STAT3 phosphorylation (not STAT6 or STAT5). STAT3 binds the STAT6 consensus site in the CCL11 promoter upon IL-17A stimulation; dominant-negative STAT3β abolishes IL-17A-induced CCL11 promoter activity; STAT3 siRNA knockdown reduces CCL11 mRNA and protein. IL-17A-induced STAT3 phosphorylation is sensitive to JAK2 and ERK1/2 inhibitors.","method":"Promoter reporter assay, EMSA/ChIP (in vivo binding), dominant-negative and siRNA knockdown of STAT3, JAK2/ERK inhibitors, ELISA, RT-PCR","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal methods (ChIP, DN overexpression, siRNA knockdown, pharmacologic inhibition) in single lab dissecting IL-17A→JAK2/ERK→STAT3→CCL11 axis","pmids":["19265112"],"is_preprint":false},{"year":2005,"finding":"Eotaxin-1 and eotaxin-2 act synergistically to recruit eosinophils to the lung in an OVA asthma model via CCR3. Individual deletion of eotaxin-1 or eotaxin-2 had modest effects on tissue eosinophilia, but eotaxin-1/2 double-knockout mice showed a marked decrease approaching the level seen in CCR3-deficient mice, establishing epistasis: CCL11 and CCL24 act redundantly upstream of CCR3 to drive peribronchial/perivascular eosinophil accumulation.","method":"Targeted gene deletion (eotaxin-1 KO, eotaxin-2 KO, DKO, CCR3 KO), OVA allergy model, BAL and tissue eosinophil counts, histology","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with four genotypes (single KO, DKO, CCR3 KO) plus defined phenotypic readout; rigorous in vivo study","pmids":["16210640"],"is_preprint":false},{"year":2014,"finding":"Crystal/NMR structure of CCL11 bound to sulfotyrosine-containing N-terminal peptide of CCR3 (residues 8–23, with two sulfotyrosine residues): sulfotyrosines make hydrophobic, salt bridge and cation-π interactions with conserved CC chemokine residues. Intact CCR3 is sulfated, and sulfation enhances receptor activity. The CCR3 N-terminus orients differently relative to CCL11 than CXC chemokine receptor N-termini do relative to their ligands.","method":"NMR/structural determination of CCL11-CCR3 peptide complex, tyrosine sulfation mutagenesis, functional receptor activity assays","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Strong — NMR structure with functional validation and sulfation mutagenesis; establishes structural basis of receptor recognition","pmids":["25450766"],"is_preprint":false},{"year":2005,"finding":"CCL11 (eotaxin-1) has a direct profibrogenic effect on human lung fibroblasts via CCR3. CCR3 is constitutively expressed on lung/bronchial fibroblasts. CCL11 increased fibroblast proliferation, MMP-2 activity, collagen synthesis, and migration; enhanced migration was completely blocked by anti-CCR3 neutralizing antibodies. CCL11 did not induce myofibroblast differentiation, contractility, or TGF-β1 release.","method":"Flow cytometry, RT-PCR, Northern blot, Boyden chamber migration, thymidine/proline incorporation, gelatin zymography, ELISA, anti-CCR3 neutralization","journal":"The Journal of allergy and clinical immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal functional assays with receptor-blocking antibody; single lab","pmids":["16387592"],"is_preprint":false},{"year":2015,"finding":"CCL11 released from activated astrocytes is taken up by microglia expressing CCR3; CCL11 promotes microglial migration and induces microglial production of reactive oxygen species by upregulating NADPH oxidase 1 (NOX1), thereby enhancing excitotoxic neuronal death. These effects were reversed by NOX1 inhibition.","method":"Primary astrocyte/microglia cultures, CCL11 neutralization/addition, ROS measurement, NOX1 inhibitor, migration assay, neuronal toxicity assay","journal":"Glia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacologic inhibition of NOX1 reverses CCL11-mediated ROS and neurotoxicity; multiple cell-type co-culture experiments; single lab","pmids":["26184677"],"is_preprint":false},{"year":2001,"finding":"Intestinal enterocyte-derived CCL11 drives gastrointestinal eosinophilia via a β7-integrin-dependent mechanism. Transgenic mice overexpressing eotaxin in intestinal epithelium (via FABPI promoter) showed significantly elevated lamina propria eosinophil counts; eotaxin-induced intestinal eosinophilia was substantially higher than IL-5-induced eosinophilia; genetic rescue of CCL11-deficient mice by eotaxin transgene restored gastrointestinal eosinophil levels; β7 integrin blockade abrogated eotaxin-induced intestinal eosinophilia.","method":"Transgenic mouse overexpression, eotaxin KO rescue experiments, β7 integrin knockout/blockade, intestinal eosinophil quantification","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (transgenic OE, KO rescue, integrin KO) converging on β7-integrin-dependent intestinal eosinophil trafficking","pmids":["11733500"],"is_preprint":false},{"year":2007,"finding":"TLR3 signaling via an intracellular (endosomal) pool mediates dsRNA-induced CCL11 synthesis in bronchial smooth muscle cells. Poly(I:C) induced CCL11 and RANTES production; TLR3-specific siRNA knockdown and bafilomycin A1 (endosomal acidification inhibitor) prominently inhibited CCL11 synthesis; surface anti-TLR3 antibody did not block poly(I:C)-induced CCL11, and TLR3 co-localized intracellularly with poly(I:C). IL-4 synergistically increased poly(I:C)-induced CCL11, and eosinophil chemotaxis driven by conditioned medium was mostly blocked by anti-CCL11 antibody.","method":"TLR3 siRNA knockdown, bafilomycin A1 inhibition, confocal microscopy (TLR3/poly(I:C) co-localization), anti-TLR3 surface blockade, chemotaxis assay with neutralizing antibody","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — siRNA knockdown, pharmacologic inhibitor, and localization data all converging on endosomal TLR3; multiple orthogonal methods in single lab","pmids":["17182588"],"is_preprint":false},{"year":2012,"finding":"TGF-β1 synergizes with IL-13 to increase CCL11 expression in human airway fibroblasts via STAT6. TGF-β1 activates MEK/ERK to reduce IL-13Rα2 expression, overcoming IL-13's negative autoregulatory feedback on its own receptor, thereby augmenting STAT6 phosphorylation, nuclear translocation, and binding to the CCL11 promoter. STAT6 siRNA knockdown abolished both STAT6 activity and CCL11 expression. Transcriptional (nuclear run-on) and posttranscriptional (mRNA stability) assays confirmed transcriptional control is dominant.","method":"Nuclear run-on, mRNA stability assay, STAT6 siRNA knockdown, MEK/ERK inhibitors, STAT6 ChIP, ELISA","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mechanistic dissection with nuclear run-on, ChIP, siRNA, and pharmacologic inhibitors; single lab with multiple orthogonal approaches","pmids":["22573806"],"is_preprint":false},{"year":2013,"finding":"Myeloid cell-specific NF-κB (RelA/p65) is required for CCL11 expression and eosinophilic inflammation in experimental colitis. RelA/p65-deficient myeloid cells showed attenuated Ccl11 expression and eosinophil recruitment in DSS colitis. In vitro, calprotectin (S100a8/S100a9) induced CCL11 production from macrophages in a p65-dependent manner. STAT-6 was not required for the macrophage CCL11 response.","method":"Myeloid-specific p65 KO mice (RelA/p65Δmye), DSS colitis model, STAT6 KO comparison, bone marrow-derived macrophage stimulation, gene array","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined cellular and molecular phenotype; single lab","pmids":["23562811"],"is_preprint":false},{"year":2011,"finding":"CCL11 (eotaxin-1) expression in hepatocytes is trans-activated by the chromatin remodeling factor Brg1 in cooperation with NF-κB/RelA. Brg1 directly binds the proximal eotaxin promoter and activates transcription. NF-κB knockdown or inhibition blocked Brg1 recruitment to the promoter and prevented eotaxin induction. Liver-specific Brg1 deletion attenuated eosinophil infiltration and eotaxin expression; adenoviral CCL11 overexpression rescued the delayed liver regeneration caused by Brg1 deficiency.","method":"ChIP (Brg1 binding to eotaxin promoter), liver-specific Brg1 KO, adenoviral CCL11 overexpression/RNAi rescue, NF-κB inhibition, ELISA, qPCR","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirms direct promoter binding; genetic rescue experiments in vivo; single lab","pmids":["35614068"],"is_preprint":false},{"year":2024,"finding":"ATX-LPA signaling suppresses CCL11 expression via an autocrine feedback loop in which LPA negatively regulates the AP-1 transcription factor c-Jun, which in turn suppresses CCL11 transcription, thereby reducing eosinophil accumulation in the pancreatic ductal adenocarcinoma microenvironment. Genetic or pharmacologic ATX inhibition increased intratumor CCL11, eosinophil numbers, and tumor cell apoptosis.","method":"Genetic ATX knockout, pharmacologic ATX inhibition, c-Jun activity assays, CCL11 promoter analysis, intratumor eosinophil quantification, tumor progression measurement","journal":"Nature cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacologic inhibition with mechanistic AP-1/c-Jun dissection; single lab","pmids":["38195933"],"is_preprint":false},{"year":2011,"finding":"IL-33 induces CCL11 (eotaxin-1) production in mouse lung fibroblasts; IL-33 and IL-13 synergistically induce CCL11 expression, as demonstrated by cytokine treatment of primary murine lung fibroblasts and the OVA asthma model.","method":"Primary murine lung fibroblast culture, cytokine stimulation, qPCR, ELISA, OVA mouse model","journal":"International archives of allergy and immunology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single cytokine stimulation experiment in cultured fibroblasts; no receptor blockade or signaling pathway dissection","pmids":["21646790"],"is_preprint":false},{"year":2003,"finding":"Oncostatin M (OSM) induces CCL11 production and mRNA expression in fibroblasts via ERK1/2 and p38 MAPK pathways (not STAT3 alone). STAT3 was activated by OSM, LIF, IL-6, and CT-1, but only OSM induced eotaxin; MEK inhibitor (PD98059) and p38 inhibitor (SB203580) partially reduced OSM-induced CCL11, indicating partial dependence on MAPK signaling. In vivo OSM overexpression caused eosinophil infiltration with elevated CCL11 mRNA.","method":"NIH 3T3/mouse lung fibroblast cultures, cytokine stimulation, MAPK inhibitors, STAT3 phosphorylation assay, adenovirus-mediated OSM overexpression in mice","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacologic dissection in vitro with in vivo confirmation; single lab","pmids":["12496442"],"is_preprint":false},{"year":2009,"finding":"CCL11 stimulates proliferation and migration/invasion of ovarian carcinoma cell lines via CCR2, CCR3, and CCR5 (all three expressed on ovarian tumors). Neutralizing antibodies against each receptor inhibited these effects. CCL11-mediated proliferative effects were associated with activation of ERK1/2, MEK1, and STAT3 phosphorylation and increased production of cytokines and angiogenic factors.","method":"Neutralizing antibodies against CCR2, CCR3, CCR5, proliferation/invasion assays, phosphoprotein analysis (ERK1/2, MEK1, STAT3), multiplex cytokine assay","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor-specific antibody blocking with multiple functional readouts; single lab","pmids":["19351767"],"is_preprint":false},{"year":2011,"finding":"CCL11 induces MMP-3 mRNA expression in human chondrocytes in a dose-dependent manner via G protein-coupled receptor (eotaxin-1/CCR3) signaling. ERK and p38 MAPK inhibitors suppressed CCL11-induced MMP-3 expression, while PKA inhibitors enhanced it. MMP-3 protein secretion was regulated by the PLC-PKC cascade and JNK/MAPK pathways. Most MMP-3 was detected in conditioned media, not cell lysates, indicating active secretion.","method":"Dose-response MMP-3 mRNA/protein assay in SW1353 and primary chondrocytes, ERK/p38/PKA/PLC/PKC/JNK inhibitors, ELISA","journal":"Journal of biomedical science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacologic pathway dissection with multiple inhibitors targeting different signaling nodes; single lab","pmids":["22114952"],"is_preprint":false},{"year":2017,"finding":"CCL11/CCR3 signaling stimulates osteoclast precursor migration and enhances bone resorption. Osteoblasts express CCL11 (increased under inflammatory conditions), while CCR3 is upregulated during osteoclast differentiation and co-localizes with CCL11. Exogenous CCL11 was internalized by osteoclasts and stimulated pre-osteoclast migration and bone resorption.","method":"In vivo inflammatory bone lesion model, primary osteoblast/osteoclast cultures, CCR3 immunostaining/co-localization, CCL11 internalization assay, migration assay, bone resorption assay","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro complementary data with receptor co-localization and functional readouts; single lab","pmids":["28706221"],"is_preprint":false},{"year":2013,"finding":"CCL11, CCL24, and CCL26 stimulate migration, invasion, and collagen IV/fibronectin adhesion of extravillous trophoblast (EVT) cells. All three eotaxins significantly increased MMP-2 activity without affecting TIMP-2 activity or cell number. This identifies a direct regulatory role for CCL11 in EVT functions critical for uterine spiral arteriole remodeling.","method":"xCELLigence real-time migration assay, wound-healing assay, Matrigel invasion assay, zymography, adhesion assay with extracellular matrix proteins","journal":"Human reproduction","confidence":"Low","confidence_rationale":"Tier 3 / Weak — functional assays with recombinant protein in a cell line model; no receptor blocking or signaling pathway identification","pmids":["23477905"],"is_preprint":false},{"year":1997,"finding":"The human eotaxin (CCL11) gene is located on chromosome 17q21.1-q21.2 (by FISH) and contains regulatory elements in its 5' flanking region conserved between human and mouse, including NF-κB, IFN-γ response element, and glucocorticoid response element sites, consistent with observed cytokine and glucocorticoid regulation of gene expression.","method":"Fluorescence in situ hybridization (FISH) chromosomal localization, genomic sequencing, cross-species promoter alignment","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — FISH localization and direct genomic sequencing; regulatory element identification is sequence-based without functional mutagenesis in this paper","pmids":["9169149"],"is_preprint":false},{"year":2008,"finding":"Intestinal macrophage- and epithelial-cell-derived CCL11 is the primary driver of colonic eosinophil recruitment in pediatric ulcerative colitis and DSS colitis. In DSS-treated eotaxin-2-/- mice, eosinophil recruitment was still intact, whereas eotaxin-1/2-/- mice showed CCL11-dependent eosinophil recruitment. CCL11 expression was restricted to F4/80+CD11b+ intestinal macrophages (DSS model) and CD68+ macrophages plus basolateral intestinal epithelial cells (UC). Eosinophil-deficient mice confirmed an effector role for eosinophils in DSS disease pathology.","method":"Gene array, qPCR, DSS colitis in eotaxin-1/2 KO and eosinophil-deficient mice, immunofluorescence cell-type identification","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO epistasis in vivo plus cell-type localization; single lab","pmids":["18981162"],"is_preprint":false},{"year":2006,"finding":"Rosmarinic acid inhibits CCL11 and CCR3 expression in human dermal fibroblasts by suppressing IKK-β activity, thereby preventing IκBα phosphorylation/degradation and NF-κB nuclear translocation and DNA binding in response to TNF-α.","method":"ELISA, Western blot, NF-κB luciferase reporter, IKK-β activity assay, immunofluorescence (NF-κB nuclear translocation)","journal":"British journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — IKK-β activity assay plus reporter and nuclear translocation assays converging on NF-κB→CCL11 axis; single lab","pmids":["16604092"],"is_preprint":false}],"current_model":"CCL11 (eotaxin-1) is a secreted CC chemokine that acts primarily through CCR3 (its high-affinity receptor, expressed on eosinophils, basophils, TH2 cells, mast cells, smooth muscle cells, fibroblasts, endothelial cells, dendritic cells, neurons, and osteoclasts), signaling via Gαi to activate ERK1/2 MAPK, drive actin polymerization, and trigger calcium flux to induce chemotaxis and cellular activation; it also acts as a partial agonist at CCR2b and a full agonist at CCR5; its transcription is driven by NF-κB (downstream of TNF-α, via IKK-β), STAT6 (downstream of IL-4/IL-13), STAT3 (downstream of IL-17A via JAK2/ERK), intracellular TLR3, the chromatin remodeler Brg1/NF-κB, and is suppressed by ATX-LPA via c-Jun; the chemokine is inactivated by mast cell β-tryptase (and chymase), and its receptor interaction is structurally governed by sulfotyrosine residues in the CCR3 N-terminus that form hydrophobic, salt bridge, and cation-π contacts with conserved CCL11 residues."},"narrative":{"mechanistic_narrative":"CCL11 (eotaxin-1) is a secreted CC chemokine that drives eosinophil and TH2-cell recruitment and tissue remodeling through the G protein-coupled receptor CCR3 [PMID:8676064, PMID:8642344, PMID:9302298, PMID:16210640]. It binds CCR3 with sub-nanomolar affinity and selectively triggers calcium flux and chemotaxis in CCR3-expressing eosinophils and TH2 (but not TH1) cells [PMID:8676064, PMID:8642344, PMID:9302298]; the receptor interaction is structurally governed by sulfotyrosine residues in the CCR3 N-terminus that form hydrophobic, salt-bridge, and cation-π contacts with conserved CCL11 residues, with receptor sulfation enhancing activity [PMID:25450766]. Downstream of CCR3, CCL11 activates the ERK1/2 (p42/p44) MAPK pathway to drive actin polymerization and chemotaxis [PMID:10415066]. Beyond CCR3, CCL11 acts as a CCR5 agonist and a partial agonist/antagonist at CCR2b, where it competitively displaces MCP-1 [PMID:11264152, PMID:11559700]. CCL11 functions broadly across cell types beyond leukocytes: it induces CCR3-dependent migration of endothelial cells and angiogenesis [PMID:11390513], smooth muscle cell migration [PMID:15130922], fibroblast proliferation, collagen synthesis and profibrotic activity [PMID:16387592], osteoclast precursor migration and bone resorption [PMID:28706221], and microglial migration with NOX1-dependent reactive oxygen species production and excitotoxicity [PMID:26184677]. In vivo, CCL11 acts redundantly with eotaxin-2 (CCL24) upstream of CCR3 to drive airway eosinophilia [PMID:16210640], contributes to bleomycin-induced lung fibrosis [PMID:16314464], and drives gastrointestinal and colonic eosinophilia through β7-integrin-dependent trafficking and macrophage/epithelial sources [PMID:11733500, PMID:18981162]. CCL11 transcription is induced by TNF-α/IL-1β via NF-κB and by IL-4/IL-13 via STAT6 through distinct promoter elements [PMID:9120022, PMID:10586089, PMID:11254707], by IL-9 [PMID:15294996], by IL-17A via JAK2/ERK-driven STAT3 binding to the STAT6 site [PMID:19265112], by oncostatin M via ERK/p38 [PMID:12496442], and through Brg1/NF-κB cooperation [PMID:35614068]; it is suppressed by ATX-LPA signaling acting on c-Jun [PMID:38195933]. The active chemokine is inactivated by mast cell β-tryptase and chymase, which cleave CCL11 and abrogate its chemotactic activity [PMID:16517749].","teleology":[{"year":1996,"claim":"Establishing the receptor for a newly described eosinophil chemoattractant answered how CCL11 achieves cell-type selectivity, identifying CCR3 as its high-affinity receptor on eosinophils.","evidence":"Radioligand binding and transwell chemotaxis in CCR3-transfected cells, plus Ca2+ flux pharmacology","pmids":["8676064","8642344"],"confidence":"High","gaps":["Affinity/selectivity mapped pharmacologically but binding-site residues not defined","Downstream signaling cascade not yet resolved"]},{"year":1997,"claim":"Demonstrating CCR3 expression on TH2 (not TH1) cells extended CCL11's role beyond eosinophil recruitment to selective TH2 lymphocyte trafficking in allergy.","evidence":"Anti-CCR3 antibody subset isolation with Ca2+ and chemotaxis assays","pmids":["9302298"],"confidence":"High","gaps":["In vivo TH2 recruitment contribution relative to eosinophils not quantified"]},{"year":1999,"claim":"Dissecting the eotaxin promoter resolved how distinct inflammatory inputs converge on CCL11, mapping TNF-α→NF-κB and IL-4→STAT6 to separate functional promoter elements.","evidence":"Promoter mutagenesis, luciferase reporter, and EMSA in BEAS-2B cells","pmids":["10586089"],"confidence":"High","gaps":["Cell-type-specific weighting of the two elements not addressed","Other inducers not yet mapped"]},{"year":1999,"claim":"Placing ERK1/2 MAPK downstream of CCR3 and upstream of actin remodeling defined the intracellular signaling route linking receptor engagement to chemotaxis.","evidence":"MEK inhibitor (PD98059) with phosphorylation, intravital rolling, chemotaxis, and actin polymerization readouts","pmids":["10415066"],"confidence":"High","gaps":["Gα subunit coupling not directly demonstrated in this study","Other parallel pathways (PI3K, PLC) not dissected"]},{"year":2001,"claim":"Profiling CCL11 across additional chemokine receptors revealed it is not CCR3-exclusive but a CCR5 agonist and CCR2b partial agonist/antagonist, broadening its receptor pharmacology and cross-regulatory potential.","evidence":"Binding, Ca2+ flux, internalization, and chemotaxis assays in monocytes and CCR2b/CCR5 transfectants","pmids":["11264152","11559700"],"confidence":"High","gaps":["Physiological significance of CCR2/CCR5 engagement in vivo unclear","Structural basis of partial agonism not defined"]},{"year":2001,"claim":"Identifying angiogenic, endothelial, and β7-integrin-dependent gastrointestinal functions established that CCL11 acts directly on non-leukocyte targets and on eosinophil tissue homing beyond simple chemotaxis.","evidence":"Endothelial CAM/Matrigel/aortic-ring angiogenesis assays; transgenic overexpression, KO rescue, and integrin blockade in intestine","pmids":["11390513","11733500"],"confidence":"Medium","gaps":["Angiogenesis findings single-lab","Signaling downstream of CCR3 in endothelium not dissected"]},{"year":2004,"claim":"Expanding the inducer repertoire to IL-9, and target cells to smooth muscle, showed CCL11 is a convergence node for multiple TH2/airway cytokines acting on structural cells.","evidence":"Promoter reporter, actinomycin D chase, neutralizing antibodies (IL-9), and CCR3-blocked SMC chemotaxis","pmids":["15294996","15130922"],"confidence":"Medium","gaps":["IL-9 signaling intermediates to the promoter not fully mapped","SMC migration consequence in vivo not tested"]},{"year":2005,"claim":"Genetic epistasis and tissue-specific studies established CCL11 as functionally redundant with CCL24 upstream of CCR3 in airway eosinophilia and as a direct profibrotic and neuro-targeting effector.","evidence":"Eotaxin-1/2/CCR3 KO genotypes in OVA model; bleomycin fibrosis KO/overexpression; CCR3-blocked fibroblast assays and airway-nerve studies","pmids":["16210640","16314464","16387592","16374515"],"confidence":"High","gaps":["Mechanism of profibrotic signaling beyond CCR3 engagement not resolved","Neuronal CCL11 source vs leukocyte source contributions not separated"]},{"year":2006,"claim":"Identifying mast cell β-tryptase and chymase as CCL11-inactivating proteases defined a post-secretion control point limiting eosinophil chemotactic activity.","evidence":"Purified protease cleavage with ELISA immunoreactivity, chemotaxis, and inhibitor controls","pmids":["16517749"],"confidence":"High","gaps":["Cleavage sites not mapped","In vivo relevance of protease inactivation not demonstrated"]},{"year":2009,"claim":"Mapping the IL-17A→JAK2/ERK→STAT3 axis onto the CCL11 promoter showed that a TH17 cytokine co-opts the STAT6 consensus site, integrating CCL11 into non-TH2 inflammation.","evidence":"ChIP, dominant-negative STAT3, siRNA knockdown, and JAK2/ERK inhibitors in airway smooth muscle cells","pmids":["19265112"],"confidence":"High","gaps":["Cross-talk between STAT3 and STAT6 occupancy not resolved","In vivo IL-17A dependence not tested here"]},{"year":2013,"claim":"Defining myeloid NF-κB (RelA/p65) and Brg1/NF-κB requirements clarified cell-type-specific and chromatin-level control of CCL11 in colitis and liver regeneration.","evidence":"Myeloid-specific p65 KO in DSS colitis; ChIP and liver-specific Brg1 KO with adenoviral CCL11 rescue","pmids":["23562811","25450766","35614068"],"confidence":"Medium","gaps":["Relationship between Brg1 and the canonical promoter elements not fully integrated","STAT6-independence of macrophage response context-specific"]},{"year":2014,"claim":"Structural determination of the CCL11–CCR3 N-terminal sulfopeptide complex provided the atomic basis for receptor recognition and showed sulfotyrosine modification governs binding.","evidence":"NMR/structural determination with tyrosine-sulfation mutagenesis and functional receptor assays","pmids":["25450766"],"confidence":"High","gaps":["Structure of intact full-length receptor-ligand complex not solved","Conformational changes driving G protein activation not captured"]},{"year":2024,"claim":"Discovering ATX-LPA→c-Jun suppression of CCL11 identified a negative regulatory loop linking CCL11/eosinophils to tumor microenvironment control.","evidence":"Genetic/pharmacologic ATX inhibition with c-Jun activity, promoter analysis, and intratumor eosinophil/apoptosis quantification in PDAC","pmids":["38195933"],"confidence":"Medium","gaps":["Direct c-Jun binding to the CCL11 promoter not fully mapped","Single-lab finding in one tumor context"]},{"year":null,"claim":"How the diverse CCL11-responsive non-leukocyte cell types (osteoclasts, microglia, trophoblasts, chondrocytes) integrate CCR3 signaling into distinct functional outputs, and the physiological role of CCR2/CCR5 engagement, remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["Cell-type-specific downstream signaling logic undefined","In vivo significance of non-CCR3 receptor usage unestablished","Trophoblast and chondrocyte effects lack receptor-blocking validation"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,2,6,7]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,5]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[3,14]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,2,17]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,5,6]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[0,2]}],"complexes":[],"partners":["CCR3","CCR2","CCR5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P51671","full_name":"Eotaxin","aliases":["C-C motif chemokine 11","Eosinophil chemotactic protein","Small-inducible cytokine A11"],"length_aa":97,"mass_kda":10.7,"function":"Chemokine that plays a central role in both allergic and non-allergic inflammatory reactions by inducing the migration of different leukocyte types including eosinophils, basophils, macrophages and dendritic cells (PubMed:8597956, PubMed:33846499). Exerts its effects primarily by binding to the CCR3 receptor (PubMed:8631813). Induces also chemotaxis of endothelial cells and promotes angiogenesis by activating the PI3K/Akt pathway (PubMed:28279120)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P51671/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCL11","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCL11","total_profiled":1310},"omim":[{"mim_id":"609423","title":"HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/609423"},{"mim_id":"607714","title":"TNFAIP3-INTERACTING PROTEIN 1; TNIP1","url":"https://www.omim.org/entry/607714"},{"mim_id":"606496","title":"INTERLEUKIN 17F; IL17F","url":"https://www.omim.org/entry/606496"},{"mim_id":"605658","title":"INTERLEUKIN 25; IL25","url":"https://www.omim.org/entry/605658"},{"mim_id":"604697","title":"CHEMOKINE, CC MOTIF, LIGAND 26; CCL26","url":"https://www.omim.org/entry/604697"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":42.9},{"tissue":"lymphoid tissue","ntpm":29.6},{"tissue":"stomach 1","ntpm":33.1},{"tissue":"urinary bladder","ntpm":38.2}],"url":"https://www.proteinatlas.org/search/CCL11"},"hgnc":{"alias_symbol":["eotaxin","MGC22554"],"prev_symbol":["SCYA11"]},"alphafold":{"accession":"P51671","domains":[{"cath_id":"2.40.50.40","chopping":"32-97","consensus_level":"medium","plddt":92.4439,"start":32,"end":97}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P51671","model_url":"https://alphafold.ebi.ac.uk/files/AF-P51671-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P51671-F1-predicted_aligned_error_v6.png","plddt_mean":86.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCL11","jax_strain_url":"https://www.jax.org/strain/search?query=CCL11"},"sequence":{"accession":"P51671","fasta_url":"https://rest.uniprot.org/uniprotkb/P51671.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P51671/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P51671"}},"corpus_meta":[{"pmid":"9302298","id":"PMC_9302298","title":"Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells.","date":"1997","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9302298","citation_count":818,"is_preprint":false},{"pmid":"8676064","id":"PMC_8676064","title":"Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils.","date":"1996","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8676064","citation_count":493,"is_preprint":false},{"pmid":"8642344","id":"PMC_8642344","title":"Cloning, expression, and characterization of the human eosinophil eotaxin receptor.","date":"1996","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8642344","citation_count":441,"is_preprint":false},{"pmid":"9120022","id":"PMC_9120022","title":"Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids.","date":"1997","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9120022","citation_count":310,"is_preprint":false},{"pmid":"10379912","id":"PMC_10379912","title":"The MCP/eotaxin subfamily of CC chemokines.","date":"1999","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/10379912","citation_count":290,"is_preprint":false},{"pmid":"22580413","id":"PMC_22580413","title":"Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD.","date":"2012","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/22580413","citation_count":277,"is_preprint":false},{"pmid":"11390513","id":"PMC_11390513","title":"Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11390513","citation_count":208,"is_preprint":false},{"pmid":"16210640","id":"PMC_16210640","title":"The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16210640","citation_count":190,"is_preprint":false},{"pmid":"10586089","id":"PMC_10586089","title":"Activation of eotaxin gene transcription by NF-kappa B and STAT6 in human airway epithelial cells.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10586089","citation_count":187,"is_preprint":false},{"pmid":"7869037","id":"PMC_7869037","title":"Constitutive and allergen-induced expression of eotaxin mRNA in the guinea pig lung.","date":"1995","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7869037","citation_count":184,"is_preprint":false},{"pmid":"11686879","id":"PMC_11686879","title":"Eotaxin and the attraction of eosinophils to the asthmatic lung.","date":"2001","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/11686879","citation_count":167,"is_preprint":false},{"pmid":"10351942","id":"PMC_10351942","title":"Constitutive and cytokine-stimulated expression of eotaxin by human airway smooth muscle cells.","date":"1999","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10351942","citation_count":155,"is_preprint":false},{"pmid":"10417617","id":"PMC_10417617","title":"Enhanced expression of eotaxin and CCR3 in atopic dermatitis.","date":"1999","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/10417617","citation_count":154,"is_preprint":false},{"pmid":"11264152","id":"PMC_11264152","title":"Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11264152","citation_count":150,"is_preprint":false},{"pmid":"18981162","id":"PMC_18981162","title":"Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18981162","citation_count":137,"is_preprint":false},{"pmid":"26184677","id":"PMC_26184677","title":"CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia.","date":"2015","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/26184677","citation_count":129,"is_preprint":false},{"pmid":"10415066","id":"PMC_10415066","title":"Activation of mitogen-activated protein kinase regulates eotaxin-induced eosinophil migration.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10415066","citation_count":120,"is_preprint":false},{"pmid":"9365117","id":"PMC_9365117","title":"Role of the monocyte chemoattractant protein and eotaxin subfamily of chemokines in allergic inflammation.","date":"1997","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/9365117","citation_count":115,"is_preprint":false},{"pmid":"12623809","id":"PMC_12623809","title":"Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis.","date":"2003","source":"Ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/12623809","citation_count":114,"is_preprint":false},{"pmid":"16374515","id":"PMC_16374515","title":"Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction.","date":"2005","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16374515","citation_count":110,"is_preprint":false},{"pmid":"9240429","id":"PMC_9240429","title":"Eotaxin expression and eosinophilic inflammation in asthma.","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9240429","citation_count":109,"is_preprint":false},{"pmid":"14698143","id":"PMC_14698143","title":"Concerted expression of eotaxin-1, eotaxin-2, and eotaxin-3 in human bronchial epithelial cells.","date":"2003","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14698143","citation_count":107,"is_preprint":false},{"pmid":"17900656","id":"PMC_17900656","title":"Increased expression of eotaxin-3 distinguishes between eosinophilic esophagitis and gastroesophageal reflux disease.","date":"2007","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17900656","citation_count":102,"is_preprint":false},{"pmid":"11254707","id":"PMC_11254707","title":"STAT6 mediates eotaxin-1 expression in IL-4 or TNF-alpha-induced fibroblasts.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11254707","citation_count":97,"is_preprint":false},{"pmid":"16314464","id":"PMC_16314464","title":"Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis.","date":"2005","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16314464","citation_count":97,"is_preprint":false},{"pmid":"10069883","id":"PMC_10069883","title":"Eotaxin and monocyte chemotactic protein-4 mRNA expression in small airways of asthmatic and nonasthmatic individuals.","date":"1999","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10069883","citation_count":97,"is_preprint":false},{"pmid":"11467997","id":"PMC_11467997","title":"Rhinovirus infection up-regulates eotaxin and eotaxin-2 expression in bronchial epithelial cells.","date":"2001","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11467997","citation_count":94,"is_preprint":false},{"pmid":"11712747","id":"PMC_11712747","title":"Eotaxin and asthma.","date":"2001","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11712747","citation_count":92,"is_preprint":false},{"pmid":"19351767","id":"PMC_19351767","title":"Role of eotaxin-1 signaling in ovarian cancer.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19351767","citation_count":84,"is_preprint":false},{"pmid":"16387592","id":"PMC_16387592","title":"The CC chemokine eotaxin/CCL11 has a selective profibrogenic effect on human lung fibroblasts.","date":"2005","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16387592","citation_count":83,"is_preprint":false},{"pmid":"23015684","id":"PMC_23015684","title":"Epithelial eotaxin-2 and eotaxin-3 expression: relation to asthma severity, luminal eosinophilia and age at onset.","date":"2012","source":"Thorax","url":"https://pubmed.ncbi.nlm.nih.gov/23015684","citation_count":83,"is_preprint":false},{"pmid":"10798661","id":"PMC_10798661","title":"Synergistic induction of eotaxin expression in human keratocytes by TNF-alpha and IL-4 or IL-13.","date":"2000","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/10798661","citation_count":82,"is_preprint":false},{"pmid":"15805998","id":"PMC_15805998","title":"Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge.","date":"2005","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15805998","citation_count":81,"is_preprint":false},{"pmid":"32887304","id":"PMC_32887304","title":"CCL-11 or Eotaxin-1: An Immune Marker for Ageing and Accelerated Ageing in Neuro-Psychiatric Disorders.","date":"2020","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32887304","citation_count":79,"is_preprint":false},{"pmid":"26359802","id":"PMC_26359802","title":"CXCL13 and CCL11 Serum Levels and Lymphoma and Disease Activity in Primary Sjögren's Syndrome.","date":"2015","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/26359802","citation_count":77,"is_preprint":false},{"pmid":"15130922","id":"PMC_15130922","title":"CCL11 (Eotaxin) induces CCR3-dependent smooth muscle cell migration.","date":"2004","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15130922","citation_count":74,"is_preprint":false},{"pmid":"22777338","id":"PMC_22777338","title":"Diagnostic utility of major basic protein, eotaxin-3, and leukotriene enzyme staining in eosinophilic esophagitis.","date":"2012","source":"The American journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/22777338","citation_count":73,"is_preprint":false},{"pmid":"28706221","id":"PMC_28706221","title":"CCL11, a novel mediator of inflammatory bone resorption.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28706221","citation_count":70,"is_preprint":false},{"pmid":"11733500","id":"PMC_11733500","title":"Enterocyte expression of the eotaxin and interleukin-5 transgenes induces compartmentalized dysregulation of eosinophil trafficking.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11733500","citation_count":70,"is_preprint":false},{"pmid":"12393570","id":"PMC_12393570","title":"Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12393570","citation_count":69,"is_preprint":false},{"pmid":"18096286","id":"PMC_18096286","title":"Increased serum levels of CCL11/eotaxin in schizophrenia.","date":"2007","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/18096286","citation_count":67,"is_preprint":false},{"pmid":"11980903","id":"PMC_11980903","title":"Indomethacin causes prostaglandin D(2)-like and eotaxin-like selective responses in eosinophils and basophils.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11980903","citation_count":67,"is_preprint":false},{"pmid":"21266446","id":"PMC_21266446","title":"Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study.","date":"2011","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21266446","citation_count":67,"is_preprint":false},{"pmid":"24796647","id":"PMC_24796647","title":"CCL11 as a potential diagnostic marker for asthma?","date":"2014","source":"The Journal of asthma : official journal of the Association for the Care of Asthma","url":"https://pubmed.ncbi.nlm.nih.gov/24796647","citation_count":66,"is_preprint":false},{"pmid":"25450766","id":"PMC_25450766","title":"Structural basis of receptor sulfotyrosine recognition by a CC chemokine: the N-terminal region of CCR3 bound to CCL11/eotaxin-1.","date":"2014","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/25450766","citation_count":66,"is_preprint":false},{"pmid":"10642580","id":"PMC_10642580","title":"Expression of the chemokine eotaxin and its receptor, CCR3, in human endometrium.","date":"2000","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/10642580","citation_count":65,"is_preprint":false},{"pmid":"24786916","id":"PMC_24786916","title":"From airway inflammation to inflammatory bowel disease: eotaxin-1, a key regulator of intestinal inflammation.","date":"2014","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/24786916","citation_count":64,"is_preprint":false},{"pmid":"15294996","id":"PMC_15294996","title":"IL-9-mediated induction of eotaxin1/CCL11 in human airway smooth muscle cells.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15294996","citation_count":64,"is_preprint":false},{"pmid":"19265112","id":"PMC_19265112","title":"Critical role for STAT3 in IL-17A-mediated CCL11 expression in human airway smooth muscle cells.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19265112","citation_count":63,"is_preprint":false},{"pmid":"11559700","id":"PMC_11559700","title":"The CC chemokine eotaxin (CCL11) is a partial agonist of CC chemokine receptor 2b.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11559700","citation_count":61,"is_preprint":false},{"pmid":"12061839","id":"PMC_12061839","title":"Regulation of human eotaxin-3/CCL26 expression: modulation by cytokines and glucocorticoids.","date":"2002","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/12061839","citation_count":59,"is_preprint":false},{"pmid":"10902814","id":"PMC_10902814","title":"Localization in tissues and secretion of eotaxin by cells from normal endometrium and endometriosis.","date":"2000","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10902814","citation_count":58,"is_preprint":false},{"pmid":"16517749","id":"PMC_16517749","title":"Mast cell beta-tryptase selectively cleaves eotaxin and RANTES and abrogates their eosinophil chemotactic activities.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16517749","citation_count":56,"is_preprint":false},{"pmid":"26861136","id":"PMC_26861136","title":"An Overlook to the Characteristics and Roles Played by Eotaxin Network in the Pathophysiology of Food Allergies: Allergic Asthma and Atopic Dermatitis.","date":"2016","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/26861136","citation_count":55,"is_preprint":false},{"pmid":"10913244","id":"PMC_10913244","title":"NMR solution structure and receptor peptide binding of the CC chemokine eotaxin-2.","date":"2000","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10913244","citation_count":54,"is_preprint":false},{"pmid":"17908961","id":"PMC_17908961","title":"Eotaxin-2 and colorectal cancer: a potential target for immune therapy.","date":"2007","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17908961","citation_count":54,"is_preprint":false},{"pmid":"12496442","id":"PMC_12496442","title":"Oncostatin M regulates eotaxin expression in fibroblasts and eosinophilic inflammation in C57BL/6 mice.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12496442","citation_count":53,"is_preprint":false},{"pmid":"16604092","id":"PMC_16604092","title":"Rosmarinic acid as a downstream inhibitor of IKK-beta in TNF-alpha-induced upregulation of CCL11 and CCR3.","date":"2006","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16604092","citation_count":53,"is_preprint":false},{"pmid":"12218106","id":"PMC_12218106","title":"Expression of a functional eotaxin (CC chemokine ligand 11) receptor CCR3 by human dendritic cells.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12218106","citation_count":52,"is_preprint":false},{"pmid":"20143648","id":"PMC_20143648","title":"Eotaxin-2/CCL24 and eotaxin-3/CCL26 exert differential profibrogenic effects on human lung fibroblasts.","date":"2010","source":"Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20143648","citation_count":51,"is_preprint":false},{"pmid":"23059958","id":"PMC_23059958","title":"CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer.","date":"2012","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/23059958","citation_count":51,"is_preprint":false},{"pmid":"35690992","id":"PMC_35690992","title":"Eotaxin-1 (CCL11) in neuroinflammatory disorders and possible role in COVID-19 neurologic complications.","date":"2022","source":"Acta neurologica Belgica","url":"https://pubmed.ncbi.nlm.nih.gov/35690992","citation_count":49,"is_preprint":false},{"pmid":"9169149","id":"PMC_9169149","title":"Genomic organization, complete sequence, and chromosomal location of the gene for human eotaxin (SCYA11), an eosinophil-specific CC chemokine.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9169149","citation_count":49,"is_preprint":false},{"pmid":"14629326","id":"PMC_14629326","title":"Eotaxin expression in oral squamous cell carcinomas with and without tumour associated tissue eosinophilia.","date":"2003","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/14629326","citation_count":49,"is_preprint":false},{"pmid":"15681407","id":"PMC_15681407","title":"Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection.","date":"2005","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/15681407","citation_count":49,"is_preprint":false},{"pmid":"14561201","id":"PMC_14561201","title":"Eotaxin receptor (CCR3) antagonism in asthma and allergic disease.","date":"2002","source":"Current drug targets. Inflammation and allergy","url":"https://pubmed.ncbi.nlm.nih.gov/14561201","citation_count":48,"is_preprint":false},{"pmid":"21646790","id":"PMC_21646790","title":"Expression and effects of IL-33 and ST2 in allergic bronchial asthma: IL-33 induces eotaxin production in lung fibroblasts.","date":"2011","source":"International archives of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21646790","citation_count":48,"is_preprint":false},{"pmid":"34625710","id":"PMC_34625710","title":"CCL11 exacerbates colitis and inflammation-associated colon tumorigenesis.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34625710","citation_count":47,"is_preprint":false},{"pmid":"26657310","id":"PMC_26657310","title":"Eosinophils in Colorectal Neoplasms Associated with Expression of CCL11 and CCL24.","date":"2015","source":"Journal of pathology and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26657310","citation_count":47,"is_preprint":false},{"pmid":"22815714","id":"PMC_22815714","title":"Expression of Ccl11 associates with immune response modulation and protection against neuroinflammation in rats.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22815714","citation_count":46,"is_preprint":false},{"pmid":"21985360","id":"PMC_21985360","title":"Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid.","date":"2011","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21985360","citation_count":46,"is_preprint":false},{"pmid":"22294786","id":"PMC_22294786","title":"CCL11 elicits secretion of RNases from mouse eosinophils and their cell-free granules.","date":"2012","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/22294786","citation_count":44,"is_preprint":false},{"pmid":"11394653","id":"PMC_11394653","title":"Eotaxin expression and eosinophil infiltrate in the liver of patients with drug-induced liver disease.","date":"2001","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/11394653","citation_count":44,"is_preprint":false},{"pmid":"20030665","id":"PMC_20030665","title":"Interleukin-13 directly promotes oesophagus production of CCL11 and CCL24 and the migration of eosinophils.","date":"2009","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20030665","citation_count":43,"is_preprint":false},{"pmid":"17182588","id":"PMC_17182588","title":"TLR3-mediated synthesis and release of eotaxin-1/CCL11 from human bronchial smooth muscle cells stimulated with double-stranded RNA.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17182588","citation_count":42,"is_preprint":false},{"pmid":"9731045","id":"PMC_9731045","title":"Eotaxin modulates myelopoiesis and mast cell development from embryonic hematopoietic progenitors.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9731045","citation_count":42,"is_preprint":false},{"pmid":"11991282","id":"PMC_11991282","title":"Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis.","date":"2002","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/11991282","citation_count":42,"is_preprint":false},{"pmid":"22573806","id":"PMC_22573806","title":"MAPK regulation of IL-4/IL-13 receptors contributes to the synergistic increase in CCL11/eotaxin-1 in response to TGF-β1 and IL-13 in human airway fibroblasts.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22573806","citation_count":42,"is_preprint":false},{"pmid":"14561170","id":"PMC_14561170","title":"Regulation of eosinophil migration and Th2 cell function by IL-5 and eotaxin.","date":"2003","source":"Current drug targets. Inflammation and allergy","url":"https://pubmed.ncbi.nlm.nih.gov/14561170","citation_count":41,"is_preprint":false},{"pmid":"11809592","id":"PMC_11809592","title":"Increased expression of eotaxin and its specific receptor CCR3 in bullous pemphigoid.","date":"2002","source":"European journal of dermatology : EJD","url":"https://pubmed.ncbi.nlm.nih.gov/11809592","citation_count":41,"is_preprint":false},{"pmid":"15186951","id":"PMC_15186951","title":"Threonine for alanine substitution in the eotaxin (CCL11) gene and the risk of incident myocardial infarction.","date":"2004","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/15186951","citation_count":41,"is_preprint":false},{"pmid":"20236835","id":"PMC_20236835","title":"Analysis of eotaxin 1/CCL11, eotaxin 2/CCL24 and eotaxin 3/CCL26 expression in lesional and non-lesional skin of patients with atopic dermatitis.","date":"2010","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/20236835","citation_count":41,"is_preprint":false},{"pmid":"23904440","id":"PMC_23904440","title":"CD14+CD33+ myeloid cell-CCL11-eosinophil signature in ulcerative colitis.","date":"2013","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/23904440","citation_count":40,"is_preprint":false},{"pmid":"15948978","id":"PMC_15948978","title":"Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis.","date":"2005","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15948978","citation_count":38,"is_preprint":false},{"pmid":"11576081","id":"PMC_11576081","title":"Increased plasma eotaxin in atopic dermatitis and acute urticaria in infants and children.","date":"2001","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/11576081","citation_count":38,"is_preprint":false},{"pmid":"25336190","id":"PMC_25336190","title":"Myeloid IKKβ promotes antitumor immunity by modulating CCL11 and the innate immune response.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25336190","citation_count":37,"is_preprint":false},{"pmid":"38195933","id":"PMC_38195933","title":"Autotaxin-lysolipid signaling suppresses a CCL11-eosinophil axis to promote pancreatic cancer progression.","date":"2024","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38195933","citation_count":36,"is_preprint":false},{"pmid":"14616128","id":"PMC_14616128","title":"RANTES, eotaxin and eotaxin-2 expression and production in patients with aspirin triad.","date":"2003","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/14616128","citation_count":36,"is_preprint":false},{"pmid":"21719482","id":"PMC_21719482","title":"IκBα glutathionylation and reduced histone H3 phosphorylation inhibit eotaxin and RANTES.","date":"2011","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/21719482","citation_count":36,"is_preprint":false},{"pmid":"12192108","id":"PMC_12192108","title":"Regulatory effects of eotaxin, eotaxin-2, and eotaxin-3 on eosinophil degranulation and superoxide anion generation.","date":"2002","source":"Experimental biology and medicine (Maywood, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/12192108","citation_count":36,"is_preprint":false},{"pmid":"25546419","id":"PMC_25546419","title":"Directional secretory response of double stranded RNA-induced thymic stromal lymphopoetin (TSLP) and CCL11/eotaxin-1 in human asthmatic airways.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25546419","citation_count":35,"is_preprint":false},{"pmid":"9780203","id":"PMC_9780203","title":"Expression and participation of eotaxin during mycobacterial (type 1) and schistosomal (type 2) antigen-elicited granuloma formation.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9780203","citation_count":35,"is_preprint":false},{"pmid":"12761043","id":"PMC_12761043","title":"Association of Eotaxin gene family with asthma and serum total IgE.","date":"2003","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12761043","citation_count":35,"is_preprint":false},{"pmid":"15322564","id":"PMC_15322564","title":"Expression of rat I-TAC/CXCL11/SCYA11 during central nervous system inflammation: comparison with other CXCR3 ligands.","date":"2004","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15322564","citation_count":34,"is_preprint":false},{"pmid":"22114952","id":"PMC_22114952","title":"Regulation of MMP-3 expression and secretion by the chemokine eotaxin-1 in human chondrocytes.","date":"2011","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/22114952","citation_count":34,"is_preprint":false},{"pmid":"35614068","id":"PMC_35614068","title":"Trans-activation of eotaxin-1 by Brg1 contributes to liver regeneration.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35614068","citation_count":33,"is_preprint":false},{"pmid":"11488333","id":"PMC_11488333","title":"Eotaxin and monocyte chemoattractant protein-1 in chronic eosinophilic pneumonia.","date":"2001","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/11488333","citation_count":31,"is_preprint":false},{"pmid":"24989688","id":"PMC_24989688","title":"Nasal fluid release of eotaxin-3 and eotaxin-2 in persistent sinonasal eosinophilic inflammation.","date":"2014","source":"International forum of allergy & rhinology","url":"https://pubmed.ncbi.nlm.nih.gov/24989688","citation_count":31,"is_preprint":false},{"pmid":"23562811","id":"PMC_23562811","title":"Intestinal CCL11 and eosinophilic inflammation is regulated by myeloid cell-specific RelA/p65 in mice.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23562811","citation_count":30,"is_preprint":false},{"pmid":"23477905","id":"PMC_23477905","title":"Control of extravillous trophoblast function by the eotaxins CCL11, CCL24 and CCL26.","date":"2013","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23477905","citation_count":30,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54934,"output_tokens":10209,"usd":0.158969,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20739,"output_tokens":4537,"usd":0.10856,"stage2_stop_reason":"end_turn"},"total_usd":0.267529,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"CCL11 (eotaxin) binds with high affinity to the G protein-coupled receptor CKR-3 (CCR3), which is selectively expressed on eosinophils. Cells transfected with CKR-3 cDNA specifically bound radiolabeled CCL11 and migrated in chemotaxis assays toward CCL11, RANTES, and MCP-3, but not other chemokines, establishing CCR3 as the primary CCL11 receptor on eosinophils.\",\n      \"method\": \"Radioligand binding assays, cDNA transfection, transwell chemotaxis assays, Northern blot, monoclonal antibody staining\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted binding and chemotaxis in transfected cells, replicated independently in two simultaneous papers (PMID 8676064 and 8642344)\",\n      \"pmids\": [\"8676064\", \"8642344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CCR3 expressed on eosinophils binds CCL11 with Kd ~0.1 nM, RANTES with Kd ~3.1 nM, and MCP-3 with Kd ~2.7 nM, and triggers intracellular Ca2+ flux in response to CCL11, RANTES, and MCP-3, but not MIP-1α or MIP-1β, indicating ligand selectivity and G protein-coupled signaling.\",\n      \"method\": \"Stable transfection in AML14.3D10 cells, competition binding, Ca2+ flux assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis-level receptor pharmacology, replicated across two independent labs\",\n      \"pmids\": [\"8642344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CCR3 is expressed by human TH2 (but not TH1) cells; CCL11 stimulates intracellular calcium increases and chemotaxis specifically in CCR3+ T cells, providing a mechanism for selective TH2 cell recruitment in allergic reactions.\",\n      \"method\": \"Anti-CCR3 antibody isolation of T cell subsets, intracellular Ca2+ measurement, chemotaxis assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal antibody blocking plus functional Ca2+ and chemotaxis assays; high-citation replication across allergy field\",\n      \"pmids\": [\"9302298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TNF-α and IL-1β induce CCL11 mRNA accumulation in pulmonary epithelial cell lines (A549, BEAS-2B) in a dose-dependent manner; IFN-γ enhances this induction; dexamethasone suppresses cytokine-induced CCL11 mRNA and protein secretion; cycloheximide augments induction, suggesting a labile repressor protein. These cytokine-induced increases correlate with increased CCL11 protein secretion.\",\n      \"method\": \"RT-PCR, ELISA, cycloheximide/dexamethasone pharmacologic manipulation of cultured cell lines\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods in single lab, clean dose-response; no independent replication cited\",\n      \"pmids\": [\"9120022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CCL11 gene transcription is activated by NF-κB (in response to TNF-α) and STAT6 (in response to IL-4) through distinct binding sites in the eotaxin promoter. Mutation of the NF-κB site abolished TNF-α-driven activation; mutation of the STAT6 site abolished IL-4-driven activation; double mutation abolished all transcriptional activation. EMSA confirmed factor binding to the respective promoter elements.\",\n      \"method\": \"Luciferase reporter assays with promoter deletion/mutation constructs, EMSA, transfection in BEAS-2B cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — promoter mutagenesis combined with EMSA and functional reporter assays in the same study; two distinct signaling nodes dissected\",\n      \"pmids\": [\"10586089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CCL11-induced eosinophil migration requires activation of the p42/p44 MAPK (ERK1/2) pathway. The MEK inhibitor PD98059 dramatically reduced eotaxin-induced eosinophil rolling in vivo and chemotaxis in vitro, and inhibited actin polymerization/rearrangement, placing MAPK activation downstream of CCR3 signaling and upstream of cytoskeletal remodeling during chemotaxis.\",\n      \"method\": \"In vitro phosphorylation assay, MEK inhibitor (PD98059), intravital microscopy, transwell chemotaxis, actin polymerization assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — pharmacologic inhibition with multiple orthogonal readouts (phosphorylation, rolling, chemotaxis, actin); single lab but rigorous mechanistic dissection\",\n      \"pmids\": [\"10415066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCL11 is a CCR5 agonist and a CCR2 antagonist. CCL11 at 100 nM triggered CCR5 (Ca2+ flux, receptor internalization) but did not activate CCR2 even at 1 µM, while competitively displacing MCP-1 from CCR2 and inhibiting MCP-1-induced chemotaxis and enzyme release. CCL11 induced CCR5 internalization in human monocytes and transfected cells.\",\n      \"method\": \"Calcium flux assay, receptor internalization assay, 125I-MCP-1 competition binding, chemotaxis assay in human monocytes and transfected cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with multiple orthogonal assays (binding, Ca2+ flux, internalization, chemotaxis); single lab\",\n      \"pmids\": [\"11264152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCL11 is a partial agonist of CCR2b. At 1 µM, CCL11 recruited CCR2b-transfected cells in chemotaxis, while sub-stimulatory concentrations inhibited MCP-1-induced chemotaxis and Ca2+ flux via CCR2b. Radiolabeled CCL11 bound CCR2b with Kd ~7.5 nM (vs. ~1.68 nM at CCR3). CCR2-specific (not CCR3-specific) antagonism blocked this CCL11-mediated migration.\",\n      \"method\": \"Radioligand binding, Ca2+ flux assay, chemotaxis assay with CCR2b/CCR3 transfectants and THP-1 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted in transfected cells with binding, Ca2+ and chemotaxis assays; complementary to PMID 11264152\",\n      \"pmids\": [\"11559700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCL11 induces chemotaxis and in vivo angiogenesis via CCR3 expressed on human microvascular endothelial cells. The chemotactic response was inhibited by antibodies to either CCL11 or CCR3. CCL11 induced blood vessel formation in chick chorioallantoic membrane and Matrigel plug assays; rat aortic ring sprouting assay showed angiogenesis is direct and not mediated by eosinophil products.\",\n      \"method\": \"Chemotaxis assay, antibody neutralization, CAM assay, Matrigel plug assay, rat aortic ring sprouting assay, flow cytometry for CCR3\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple in vivo and in vitro angiogenesis models with antibody blocking; single lab\",\n      \"pmids\": [\"11390513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TNF-α-induced CCL11 expression in fibroblasts is mediated through STAT6, not solely NF-κB. TNF-α activated the CCL11 promoter via an NF-κB/STAT6 composite element, and this required STAT6 DNA binding; promoter constructs with mutated STAT6 sites were unresponsive to TNF-α. A trans-dominant negative STAT6 protein inhibited TNF-α-induced CCL11 secretion in primary fibroblasts.\",\n      \"method\": \"Luciferase promoter reporter in STAT6-deficient HEK293 cells with STAT6 cotransfection, dominant-negative STAT6 overexpression, ELISA\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — promoter mutagenesis, dominant-negative rescue, and protein secretion readout in a single study\",\n      \"pmids\": [\"11254707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CCL11 induces CCR3-dependent smooth muscle cell (SMC) migration. CCR3 mRNA and protein are expressed in mouse aortic SMCs; CCL11 induced concentration-dependent SMC chemotaxis in Boyden chamber and scrape-wound assays that were blocked by anti-CCR3 (but not anti-CCR2) antibody. CCL11 had no effect on SMC proliferation.\",\n      \"method\": \"RT-PCR, Western blot, flow cytometry, Boyden chamber chemotaxis, scrape-wound assay, antibody neutralization\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple assays with receptor-specific antibody blocking; single lab\",\n      \"pmids\": [\"15130922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CCL11 signaling via CCR3 mediates eosinophil recruitment specifically to airway nerves (not just to lung tissue broadly) in antigen-challenged guinea pigs. A CCR3 antagonist prevented clustering of eosinophils around nerves and preserved M2 muscarinic receptor function, blocking vagal hyperreactivity. CCL11 protein was detected in airway parasympathetic neurons; IL-4 and IL-13 increased CCL11 expression in cultured airway neurons and human neuroblastoma cells.\",\n      \"method\": \"In vivo CCR3 antagonist treatment, immunostaining of airway nerves, M2R functional assay (vagal stimulation), cultured guinea pig and human airway neurons\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo pharmacologic blockade with mechanistic endpoint (nerve clustering, M2R function), supported by neuronal expression data; single lab\",\n      \"pmids\": [\"16374515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CCL11 and CCR3 are required for pulmonary granulocyte recruitment and development of bleomycin-induced lung fibrosis. CCL11-deficient mice developed significantly reduced fibrosis and lower TGF-β1 expression; overexpression of CCL11 enhanced fibrosis. Neutralizing CCR3 antibodies reduced fibrosis, eosinophilia, neutrophilia, and profibrotic cytokines.\",\n      \"method\": \"CCL11 knockout mice, CCL11 overexpression, anti-CCR3 antibody neutralization, histology, cytokine measurement\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function and antibody blocking with defined fibrotic phenotype; single lab\",\n      \"pmids\": [\"16314464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CCL11 directly activates mouse eosinophil secretion of enzymatically active RNases (EARs) by piecemeal degranulation (EC50 ~5 nM), via CCR3 on both intact eosinophils and cell-free eosinophil granules. Cell-free granules expressing functional CCR3 secreted EAR and eosinophil peroxidase in response to CCL11.\",\n      \"method\": \"In vitro RNase activity assay, ultrastructural electron microscopy (piecemeal degranulation), CCR3-expressing cell-free granule stimulation\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional in vitro assay with ultrastructural validation; single lab\",\n      \"pmids\": [\"22294786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Mast cell β-tryptase selectively cleaves CCL11 (eotaxin) and RANTES, abrogating their eosinophil chemotactic activities. The proteolytic activity of tryptase (requiring heparin) was necessary; heat inactivation and leupeptin reversed the effect. Mast cell chymase also reduced CCL11 immunoreactivity but did not affect RANTES. Neither enzyme affected other tested chemokines/cytokines.\",\n      \"method\": \"Purified β-tryptase incubation with recombinant and cell-derived CCL11/RANTES, ELISA immunoreactivity, chemotaxis assay with tryptase-pretreated chemokines, protease inhibitor and heat-inactivation controls\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical cleavage assay with functional chemotaxis readout and enzyme inhibitor controls; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"16517749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IL-9 induces CCL11 expression in human airway smooth muscle (ASM) cells via transcriptional activation of the CCL11 promoter. IL-9Rα is expressed on ASM cells; neutralizing anti-IL-9 (but not anti-IL-4 or anti-IL-13) antibodies significantly reduced IL-9-induced CCL11 production. Actinomycin D blocked IL-9-induced CCL11 mRNA and protein, confirming transcriptional regulation. Conditioned medium from IL-9-stimulated ASM cells attracted eosinophils.\",\n      \"method\": \"ELISA, real-time RT-PCR, luciferase promoter reporter transfection, neutralizing antibody blockade, actinomycin D chase, chemotaxis assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — transcriptional mechanism confirmed by promoter reporter and actinomycin D, with functional chemotaxis readout; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"15294996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"IL-17A induces CCL11 expression in human airway smooth muscle cells via STAT3 phosphorylation (not STAT6 or STAT5). STAT3 binds the STAT6 consensus site in the CCL11 promoter upon IL-17A stimulation; dominant-negative STAT3β abolishes IL-17A-induced CCL11 promoter activity; STAT3 siRNA knockdown reduces CCL11 mRNA and protein. IL-17A-induced STAT3 phosphorylation is sensitive to JAK2 and ERK1/2 inhibitors.\",\n      \"method\": \"Promoter reporter assay, EMSA/ChIP (in vivo binding), dominant-negative and siRNA knockdown of STAT3, JAK2/ERK inhibitors, ELISA, RT-PCR\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal methods (ChIP, DN overexpression, siRNA knockdown, pharmacologic inhibition) in single lab dissecting IL-17A→JAK2/ERK→STAT3→CCL11 axis\",\n      \"pmids\": [\"19265112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Eotaxin-1 and eotaxin-2 act synergistically to recruit eosinophils to the lung in an OVA asthma model via CCR3. Individual deletion of eotaxin-1 or eotaxin-2 had modest effects on tissue eosinophilia, but eotaxin-1/2 double-knockout mice showed a marked decrease approaching the level seen in CCR3-deficient mice, establishing epistasis: CCL11 and CCL24 act redundantly upstream of CCR3 to drive peribronchial/perivascular eosinophil accumulation.\",\n      \"method\": \"Targeted gene deletion (eotaxin-1 KO, eotaxin-2 KO, DKO, CCR3 KO), OVA allergy model, BAL and tissue eosinophil counts, histology\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with four genotypes (single KO, DKO, CCR3 KO) plus defined phenotypic readout; rigorous in vivo study\",\n      \"pmids\": [\"16210640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Crystal/NMR structure of CCL11 bound to sulfotyrosine-containing N-terminal peptide of CCR3 (residues 8–23, with two sulfotyrosine residues): sulfotyrosines make hydrophobic, salt bridge and cation-π interactions with conserved CC chemokine residues. Intact CCR3 is sulfated, and sulfation enhances receptor activity. The CCR3 N-terminus orients differently relative to CCL11 than CXC chemokine receptor N-termini do relative to their ligands.\",\n      \"method\": \"NMR/structural determination of CCL11-CCR3 peptide complex, tyrosine sulfation mutagenesis, functional receptor activity assays\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — NMR structure with functional validation and sulfation mutagenesis; establishes structural basis of receptor recognition\",\n      \"pmids\": [\"25450766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CCL11 (eotaxin-1) has a direct profibrogenic effect on human lung fibroblasts via CCR3. CCR3 is constitutively expressed on lung/bronchial fibroblasts. CCL11 increased fibroblast proliferation, MMP-2 activity, collagen synthesis, and migration; enhanced migration was completely blocked by anti-CCR3 neutralizing antibodies. CCL11 did not induce myofibroblast differentiation, contractility, or TGF-β1 release.\",\n      \"method\": \"Flow cytometry, RT-PCR, Northern blot, Boyden chamber migration, thymidine/proline incorporation, gelatin zymography, ELISA, anti-CCR3 neutralization\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal functional assays with receptor-blocking antibody; single lab\",\n      \"pmids\": [\"16387592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CCL11 released from activated astrocytes is taken up by microglia expressing CCR3; CCL11 promotes microglial migration and induces microglial production of reactive oxygen species by upregulating NADPH oxidase 1 (NOX1), thereby enhancing excitotoxic neuronal death. These effects were reversed by NOX1 inhibition.\",\n      \"method\": \"Primary astrocyte/microglia cultures, CCL11 neutralization/addition, ROS measurement, NOX1 inhibitor, migration assay, neuronal toxicity assay\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacologic inhibition of NOX1 reverses CCL11-mediated ROS and neurotoxicity; multiple cell-type co-culture experiments; single lab\",\n      \"pmids\": [\"26184677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Intestinal enterocyte-derived CCL11 drives gastrointestinal eosinophilia via a β7-integrin-dependent mechanism. Transgenic mice overexpressing eotaxin in intestinal epithelium (via FABPI promoter) showed significantly elevated lamina propria eosinophil counts; eotaxin-induced intestinal eosinophilia was substantially higher than IL-5-induced eosinophilia; genetic rescue of CCL11-deficient mice by eotaxin transgene restored gastrointestinal eosinophil levels; β7 integrin blockade abrogated eotaxin-induced intestinal eosinophilia.\",\n      \"method\": \"Transgenic mouse overexpression, eotaxin KO rescue experiments, β7 integrin knockout/blockade, intestinal eosinophil quantification\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (transgenic OE, KO rescue, integrin KO) converging on β7-integrin-dependent intestinal eosinophil trafficking\",\n      \"pmids\": [\"11733500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TLR3 signaling via an intracellular (endosomal) pool mediates dsRNA-induced CCL11 synthesis in bronchial smooth muscle cells. Poly(I:C) induced CCL11 and RANTES production; TLR3-specific siRNA knockdown and bafilomycin A1 (endosomal acidification inhibitor) prominently inhibited CCL11 synthesis; surface anti-TLR3 antibody did not block poly(I:C)-induced CCL11, and TLR3 co-localized intracellularly with poly(I:C). IL-4 synergistically increased poly(I:C)-induced CCL11, and eosinophil chemotaxis driven by conditioned medium was mostly blocked by anti-CCL11 antibody.\",\n      \"method\": \"TLR3 siRNA knockdown, bafilomycin A1 inhibition, confocal microscopy (TLR3/poly(I:C) co-localization), anti-TLR3 surface blockade, chemotaxis assay with neutralizing antibody\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — siRNA knockdown, pharmacologic inhibitor, and localization data all converging on endosomal TLR3; multiple orthogonal methods in single lab\",\n      \"pmids\": [\"17182588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TGF-β1 synergizes with IL-13 to increase CCL11 expression in human airway fibroblasts via STAT6. TGF-β1 activates MEK/ERK to reduce IL-13Rα2 expression, overcoming IL-13's negative autoregulatory feedback on its own receptor, thereby augmenting STAT6 phosphorylation, nuclear translocation, and binding to the CCL11 promoter. STAT6 siRNA knockdown abolished both STAT6 activity and CCL11 expression. Transcriptional (nuclear run-on) and posttranscriptional (mRNA stability) assays confirmed transcriptional control is dominant.\",\n      \"method\": \"Nuclear run-on, mRNA stability assay, STAT6 siRNA knockdown, MEK/ERK inhibitors, STAT6 ChIP, ELISA\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mechanistic dissection with nuclear run-on, ChIP, siRNA, and pharmacologic inhibitors; single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"22573806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Myeloid cell-specific NF-κB (RelA/p65) is required for CCL11 expression and eosinophilic inflammation in experimental colitis. RelA/p65-deficient myeloid cells showed attenuated Ccl11 expression and eosinophil recruitment in DSS colitis. In vitro, calprotectin (S100a8/S100a9) induced CCL11 production from macrophages in a p65-dependent manner. STAT-6 was not required for the macrophage CCL11 response.\",\n      \"method\": \"Myeloid-specific p65 KO mice (RelA/p65Δmye), DSS colitis model, STAT6 KO comparison, bone marrow-derived macrophage stimulation, gene array\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined cellular and molecular phenotype; single lab\",\n      \"pmids\": [\"23562811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CCL11 (eotaxin-1) expression in hepatocytes is trans-activated by the chromatin remodeling factor Brg1 in cooperation with NF-κB/RelA. Brg1 directly binds the proximal eotaxin promoter and activates transcription. NF-κB knockdown or inhibition blocked Brg1 recruitment to the promoter and prevented eotaxin induction. Liver-specific Brg1 deletion attenuated eosinophil infiltration and eotaxin expression; adenoviral CCL11 overexpression rescued the delayed liver regeneration caused by Brg1 deficiency.\",\n      \"method\": \"ChIP (Brg1 binding to eotaxin promoter), liver-specific Brg1 KO, adenoviral CCL11 overexpression/RNAi rescue, NF-κB inhibition, ELISA, qPCR\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirms direct promoter binding; genetic rescue experiments in vivo; single lab\",\n      \"pmids\": [\"35614068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ATX-LPA signaling suppresses CCL11 expression via an autocrine feedback loop in which LPA negatively regulates the AP-1 transcription factor c-Jun, which in turn suppresses CCL11 transcription, thereby reducing eosinophil accumulation in the pancreatic ductal adenocarcinoma microenvironment. Genetic or pharmacologic ATX inhibition increased intratumor CCL11, eosinophil numbers, and tumor cell apoptosis.\",\n      \"method\": \"Genetic ATX knockout, pharmacologic ATX inhibition, c-Jun activity assays, CCL11 promoter analysis, intratumor eosinophil quantification, tumor progression measurement\",\n      \"journal\": \"Nature cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacologic inhibition with mechanistic AP-1/c-Jun dissection; single lab\",\n      \"pmids\": [\"38195933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IL-33 induces CCL11 (eotaxin-1) production in mouse lung fibroblasts; IL-33 and IL-13 synergistically induce CCL11 expression, as demonstrated by cytokine treatment of primary murine lung fibroblasts and the OVA asthma model.\",\n      \"method\": \"Primary murine lung fibroblast culture, cytokine stimulation, qPCR, ELISA, OVA mouse model\",\n      \"journal\": \"International archives of allergy and immunology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single cytokine stimulation experiment in cultured fibroblasts; no receptor blockade or signaling pathway dissection\",\n      \"pmids\": [\"21646790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Oncostatin M (OSM) induces CCL11 production and mRNA expression in fibroblasts via ERK1/2 and p38 MAPK pathways (not STAT3 alone). STAT3 was activated by OSM, LIF, IL-6, and CT-1, but only OSM induced eotaxin; MEK inhibitor (PD98059) and p38 inhibitor (SB203580) partially reduced OSM-induced CCL11, indicating partial dependence on MAPK signaling. In vivo OSM overexpression caused eosinophil infiltration with elevated CCL11 mRNA.\",\n      \"method\": \"NIH 3T3/mouse lung fibroblast cultures, cytokine stimulation, MAPK inhibitors, STAT3 phosphorylation assay, adenovirus-mediated OSM overexpression in mice\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacologic dissection in vitro with in vivo confirmation; single lab\",\n      \"pmids\": [\"12496442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CCL11 stimulates proliferation and migration/invasion of ovarian carcinoma cell lines via CCR2, CCR3, and CCR5 (all three expressed on ovarian tumors). Neutralizing antibodies against each receptor inhibited these effects. CCL11-mediated proliferative effects were associated with activation of ERK1/2, MEK1, and STAT3 phosphorylation and increased production of cytokines and angiogenic factors.\",\n      \"method\": \"Neutralizing antibodies against CCR2, CCR3, CCR5, proliferation/invasion assays, phosphoprotein analysis (ERK1/2, MEK1, STAT3), multiplex cytokine assay\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor-specific antibody blocking with multiple functional readouts; single lab\",\n      \"pmids\": [\"19351767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CCL11 induces MMP-3 mRNA expression in human chondrocytes in a dose-dependent manner via G protein-coupled receptor (eotaxin-1/CCR3) signaling. ERK and p38 MAPK inhibitors suppressed CCL11-induced MMP-3 expression, while PKA inhibitors enhanced it. MMP-3 protein secretion was regulated by the PLC-PKC cascade and JNK/MAPK pathways. Most MMP-3 was detected in conditioned media, not cell lysates, indicating active secretion.\",\n      \"method\": \"Dose-response MMP-3 mRNA/protein assay in SW1353 and primary chondrocytes, ERK/p38/PKA/PLC/PKC/JNK inhibitors, ELISA\",\n      \"journal\": \"Journal of biomedical science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacologic pathway dissection with multiple inhibitors targeting different signaling nodes; single lab\",\n      \"pmids\": [\"22114952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CCL11/CCR3 signaling stimulates osteoclast precursor migration and enhances bone resorption. Osteoblasts express CCL11 (increased under inflammatory conditions), while CCR3 is upregulated during osteoclast differentiation and co-localizes with CCL11. Exogenous CCL11 was internalized by osteoclasts and stimulated pre-osteoclast migration and bone resorption.\",\n      \"method\": \"In vivo inflammatory bone lesion model, primary osteoblast/osteoclast cultures, CCR3 immunostaining/co-localization, CCL11 internalization assay, migration assay, bone resorption assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro complementary data with receptor co-localization and functional readouts; single lab\",\n      \"pmids\": [\"28706221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CCL11, CCL24, and CCL26 stimulate migration, invasion, and collagen IV/fibronectin adhesion of extravillous trophoblast (EVT) cells. All three eotaxins significantly increased MMP-2 activity without affecting TIMP-2 activity or cell number. This identifies a direct regulatory role for CCL11 in EVT functions critical for uterine spiral arteriole remodeling.\",\n      \"method\": \"xCELLigence real-time migration assay, wound-healing assay, Matrigel invasion assay, zymography, adhesion assay with extracellular matrix proteins\",\n      \"journal\": \"Human reproduction\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — functional assays with recombinant protein in a cell line model; no receptor blocking or signaling pathway identification\",\n      \"pmids\": [\"23477905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The human eotaxin (CCL11) gene is located on chromosome 17q21.1-q21.2 (by FISH) and contains regulatory elements in its 5' flanking region conserved between human and mouse, including NF-κB, IFN-γ response element, and glucocorticoid response element sites, consistent with observed cytokine and glucocorticoid regulation of gene expression.\",\n      \"method\": \"Fluorescence in situ hybridization (FISH) chromosomal localization, genomic sequencing, cross-species promoter alignment\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — FISH localization and direct genomic sequencing; regulatory element identification is sequence-based without functional mutagenesis in this paper\",\n      \"pmids\": [\"9169149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Intestinal macrophage- and epithelial-cell-derived CCL11 is the primary driver of colonic eosinophil recruitment in pediatric ulcerative colitis and DSS colitis. In DSS-treated eotaxin-2-/- mice, eosinophil recruitment was still intact, whereas eotaxin-1/2-/- mice showed CCL11-dependent eosinophil recruitment. CCL11 expression was restricted to F4/80+CD11b+ intestinal macrophages (DSS model) and CD68+ macrophages plus basolateral intestinal epithelial cells (UC). Eosinophil-deficient mice confirmed an effector role for eosinophils in DSS disease pathology.\",\n      \"method\": \"Gene array, qPCR, DSS colitis in eotaxin-1/2 KO and eosinophil-deficient mice, immunofluorescence cell-type identification\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO epistasis in vivo plus cell-type localization; single lab\",\n      \"pmids\": [\"18981162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Rosmarinic acid inhibits CCL11 and CCR3 expression in human dermal fibroblasts by suppressing IKK-β activity, thereby preventing IκBα phosphorylation/degradation and NF-κB nuclear translocation and DNA binding in response to TNF-α.\",\n      \"method\": \"ELISA, Western blot, NF-κB luciferase reporter, IKK-β activity assay, immunofluorescence (NF-κB nuclear translocation)\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — IKK-β activity assay plus reporter and nuclear translocation assays converging on NF-κB→CCL11 axis; single lab\",\n      \"pmids\": [\"16604092\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCL11 (eotaxin-1) is a secreted CC chemokine that acts primarily through CCR3 (its high-affinity receptor, expressed on eosinophils, basophils, TH2 cells, mast cells, smooth muscle cells, fibroblasts, endothelial cells, dendritic cells, neurons, and osteoclasts), signaling via Gαi to activate ERK1/2 MAPK, drive actin polymerization, and trigger calcium flux to induce chemotaxis and cellular activation; it also acts as a partial agonist at CCR2b and a full agonist at CCR5; its transcription is driven by NF-κB (downstream of TNF-α, via IKK-β), STAT6 (downstream of IL-4/IL-13), STAT3 (downstream of IL-17A via JAK2/ERK), intracellular TLR3, the chromatin remodeler Brg1/NF-κB, and is suppressed by ATX-LPA via c-Jun; the chemokine is inactivated by mast cell β-tryptase (and chymase), and its receptor interaction is structurally governed by sulfotyrosine residues in the CCR3 N-terminus that form hydrophobic, salt bridge, and cation-π contacts with conserved CCL11 residues.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CCL11 (eotaxin-1) is a secreted CC chemokine that drives eosinophil and TH2-cell recruitment and tissue remodeling through the G protein-coupled receptor CCR3 [#0, #2, #17]. It binds CCR3 with sub-nanomolar affinity and selectively triggers calcium flux and chemotaxis in CCR3-expressing eosinophils and TH2 (but not TH1) cells [#0, #1, #2]; the receptor interaction is structurally governed by sulfotyrosine residues in the CCR3 N-terminus that form hydrophobic, salt-bridge, and cation-\\u03c0 contacts with conserved CCL11 residues, with receptor sulfation enhancing activity [#18]. Downstream of CCR3, CCL11 activates the ERK1/2 (p42/p44) MAPK pathway to drive actin polymerization and chemotaxis [#5]. Beyond CCR3, CCL11 acts as a CCR5 agonist and a partial agonist/antagonist at CCR2b, where it competitively displaces MCP-1 [#6, #7]. CCL11 functions broadly across cell types beyond leukocytes: it induces CCR3-dependent migration of endothelial cells and angiogenesis [#8], smooth muscle cell migration [#10], fibroblast proliferation, collagen synthesis and profibrotic activity [#19], osteoclast precursor migration and bone resorption [#31], and microglial migration with NOX1-dependent reactive oxygen species production and excitotoxicity [#20]. In vivo, CCL11 acts redundantly with eotaxin-2 (CCL24) upstream of CCR3 to drive airway eosinophilia [#17], contributes to bleomycin-induced lung fibrosis [#12], and drives gastrointestinal and colonic eosinophilia through \\u03b27-integrin-dependent trafficking and macrophage/epithelial sources [#21, #34]. CCL11 transcription is induced by TNF-\\u03b1/IL-1\\u03b2 via NF-\\u03baB and by IL-4/IL-13 via STAT6 through distinct promoter elements [#3, #4, #9], by IL-9 [#15], by IL-17A via JAK2/ERK-driven STAT3 binding to the STAT6 site [#16], by oncostatin M via ERK/p38 [#28], and through Brg1/NF-\\u03baB cooperation [#25]; it is suppressed by ATX-LPA signaling acting on c-Jun [#26]. The active chemokine is inactivated by mast cell \\u03b2-tryptase and chymase, which cleave CCL11 and abrogate its chemotactic activity [#14].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Establishing the receptor for a newly described eosinophil chemoattractant answered how CCL11 achieves cell-type selectivity, identifying CCR3 as its high-affinity receptor on eosinophils.\",\n      \"evidence\": \"Radioligand binding and transwell chemotaxis in CCR3-transfected cells, plus Ca2+ flux pharmacology\",\n      \"pmids\": [\"8676064\", \"8642344\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Affinity/selectivity mapped pharmacologically but binding-site residues not defined\", \"Downstream signaling cascade not yet resolved\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrating CCR3 expression on TH2 (not TH1) cells extended CCL11's role beyond eosinophil recruitment to selective TH2 lymphocyte trafficking in allergy.\",\n      \"evidence\": \"Anti-CCR3 antibody subset isolation with Ca2+ and chemotaxis assays\",\n      \"pmids\": [\"9302298\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo TH2 recruitment contribution relative to eosinophils not quantified\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Dissecting the eotaxin promoter resolved how distinct inflammatory inputs converge on CCL11, mapping TNF-\\u03b1\\u2192NF-\\u03baB and IL-4\\u2192STAT6 to separate functional promoter elements.\",\n      \"evidence\": \"Promoter mutagenesis, luciferase reporter, and EMSA in BEAS-2B cells\",\n      \"pmids\": [\"10586089\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-type-specific weighting of the two elements not addressed\", \"Other inducers not yet mapped\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Placing ERK1/2 MAPK downstream of CCR3 and upstream of actin remodeling defined the intracellular signaling route linking receptor engagement to chemotaxis.\",\n      \"evidence\": \"MEK inhibitor (PD98059) with phosphorylation, intravital rolling, chemotaxis, and actin polymerization readouts\",\n      \"pmids\": [\"10415066\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"G\\u03b1 subunit coupling not directly demonstrated in this study\", \"Other parallel pathways (PI3K, PLC) not dissected\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Profiling CCL11 across additional chemokine receptors revealed it is not CCR3-exclusive but a CCR5 agonist and CCR2b partial agonist/antagonist, broadening its receptor pharmacology and cross-regulatory potential.\",\n      \"evidence\": \"Binding, Ca2+ flux, internalization, and chemotaxis assays in monocytes and CCR2b/CCR5 transfectants\",\n      \"pmids\": [\"11264152\", \"11559700\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological significance of CCR2/CCR5 engagement in vivo unclear\", \"Structural basis of partial agonism not defined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identifying angiogenic, endothelial, and \\u03b27-integrin-dependent gastrointestinal functions established that CCL11 acts directly on non-leukocyte targets and on eosinophil tissue homing beyond simple chemotaxis.\",\n      \"evidence\": \"Endothelial CAM/Matrigel/aortic-ring angiogenesis assays; transgenic overexpression, KO rescue, and integrin blockade in intestine\",\n      \"pmids\": [\"11390513\", \"11733500\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Angiogenesis findings single-lab\", \"Signaling downstream of CCR3 in endothelium not dissected\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Expanding the inducer repertoire to IL-9, and target cells to smooth muscle, showed CCL11 is a convergence node for multiple TH2/airway cytokines acting on structural cells.\",\n      \"evidence\": \"Promoter reporter, actinomycin D chase, neutralizing antibodies (IL-9), and CCR3-blocked SMC chemotaxis\",\n      \"pmids\": [\"15294996\", \"15130922\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"IL-9 signaling intermediates to the promoter not fully mapped\", \"SMC migration consequence in vivo not tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Genetic epistasis and tissue-specific studies established CCL11 as functionally redundant with CCL24 upstream of CCR3 in airway eosinophilia and as a direct profibrotic and neuro-targeting effector.\",\n      \"evidence\": \"Eotaxin-1/2/CCR3 KO genotypes in OVA model; bleomycin fibrosis KO/overexpression; CCR3-blocked fibroblast assays and airway-nerve studies\",\n      \"pmids\": [\"16210640\", \"16314464\", \"16387592\", \"16374515\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of profibrotic signaling beyond CCR3 engagement not resolved\", \"Neuronal CCL11 source vs leukocyte source contributions not separated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identifying mast cell \\u03b2-tryptase and chymase as CCL11-inactivating proteases defined a post-secretion control point limiting eosinophil chemotactic activity.\",\n      \"evidence\": \"Purified protease cleavage with ELISA immunoreactivity, chemotaxis, and inhibitor controls\",\n      \"pmids\": [\"16517749\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cleavage sites not mapped\", \"In vivo relevance of protease inactivation not demonstrated\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Mapping the IL-17A\\u2192JAK2/ERK\\u2192STAT3 axis onto the CCL11 promoter showed that a TH17 cytokine co-opts the STAT6 consensus site, integrating CCL11 into non-TH2 inflammation.\",\n      \"evidence\": \"ChIP, dominant-negative STAT3, siRNA knockdown, and JAK2/ERK inhibitors in airway smooth muscle cells\",\n      \"pmids\": [\"19265112\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cross-talk between STAT3 and STAT6 occupancy not resolved\", \"In vivo IL-17A dependence not tested here\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defining myeloid NF-\\u03baB (RelA/p65) and Brg1/NF-\\u03baB requirements clarified cell-type-specific and chromatin-level control of CCL11 in colitis and liver regeneration.\",\n      \"evidence\": \"Myeloid-specific p65 KO in DSS colitis; ChIP and liver-specific Brg1 KO with adenoviral CCL11 rescue\",\n      \"pmids\": [\"23562811\", \"25450766\", \"35614068\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relationship between Brg1 and the canonical promoter elements not fully integrated\", \"STAT6-independence of macrophage response context-specific\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Structural determination of the CCL11\\u2013CCR3 N-terminal sulfopeptide complex provided the atomic basis for receptor recognition and showed sulfotyrosine modification governs binding.\",\n      \"evidence\": \"NMR/structural determination with tyrosine-sulfation mutagenesis and functional receptor assays\",\n      \"pmids\": [\"25450766\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of intact full-length receptor-ligand complex not solved\", \"Conformational changes driving G protein activation not captured\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Discovering ATX-LPA\\u2192c-Jun suppression of CCL11 identified a negative regulatory loop linking CCL11/eosinophils to tumor microenvironment control.\",\n      \"evidence\": \"Genetic/pharmacologic ATX inhibition with c-Jun activity, promoter analysis, and intratumor eosinophil/apoptosis quantification in PDAC\",\n      \"pmids\": [\"38195933\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct c-Jun binding to the CCL11 promoter not fully mapped\", \"Single-lab finding in one tumor context\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse CCL11-responsive non-leukocyte cell types (osteoclasts, microglia, trophoblasts, chondrocytes) integrate CCR3 signaling into distinct functional outputs, and the physiological role of CCR2/CCR5 engagement, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Cell-type-specific downstream signaling logic undefined\", \"In vivo significance of non-CCR3 receptor usage unestablished\", \"Trophoblast and chondrocyte effects lack receptor-blocking validation\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 2, 6, 7]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [3, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 2, 17]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 5, 6]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CCR3\", \"CCR2\", \"CCR5\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}